1. , . Melatonin. Fed Proc 1960;19:590–2.
2. . Melatonin and human rhythms. Chronobiol Int 2006;23:21–37.
3. , , , et al. Melatonin: nature’s most versatile biological signal?FEBS J 2006;273:2813–38.
4. . Melatonin, hormone of darkness and more: occurrence, control mechanisms, actions and bioactive metabolites. Cell Mol Life Sci 2008;65:2001–18.
5. . Melatonin in human physiology and pathology. In , ed. Frontiers in Chronobiology Research. Hauppage, N:, Nova Science; 2006: pp. 1–43.
6. . The pineal gland: a neurochemical transducer. Science 1974;184:1341–8.
7. , , . Binding of melatonin to human and rat plasma proteins. Endocrinology 1972;91:1213–8.
8. , , . Estimation of frequently sampled nocturnal melatonin production in humans by deconvolution analysis: evidence for episodic or ultradian secretion. J Pineal Res 1999;27:139–44.
9. , , , . A mathematical model of diurnal variations in human plasma melatonin levels. Am J Physiol 1997;272:E506–16.
10. , , , . In vitro and in vivo formation of two new metabolites of melatonin. J Biol Chem 1974;249:1311–13.
11. , . Role of CSF in the transport of melatonin. J Pineal Res 2002;33:61
12. , , , , . One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species?J Pineal Res 2007;42:28–42.
13. . Neural control of the pineal gland. Behav Brain Res 1996;73:125–30.
14. , . The mammalian pineal gland: known facts, unknown facets. Trends Endocrinol Metab 2007;18:142–9.
15. , , . Development of melatonin production in infants and the impact of prematurity. J Clin Endocrinol Metab 1992;75:367–9.
16. . Melatonin, human aging, and age-related diseases. Exp Gerontol 2004;39:1723–9.
17. , . Reproducibility of the circadian rhythms of serum cortisol and melatonin in healthy subjects: a study of three different 24-h cycles over six weeks. Life Sci 2003;73:3339–49.
18. . Melatonin receptors: role on sleep and circadian rhythm regulation. Sleep Med 2007;8(Suppl. 3):34–42.
19. , , , et al. Melatonin, immune function and aging. Immunity Ageing 2005;2:17.
20. , , , et al. Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl- N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages. J Neuroimmunol 2005;165:139–49.
21. , , , et al. Melatonin, environmental light, and breast cancer. Breast Cancer Res Treat 2008;108:339–50.
22. , , , . Melatonin role in the mitochondrial function. Front Biosci 2007;12:947–63.
23. , , , et al. Role of melatonin in neurodegenerative diseases. Neurotox Res 2005;7:293–318.
24. , . The histological appearance of the human pineal gland from puberty to old age. J Pathol 1972;108:137–44.
25. , , . Age and enzyme activity in the human pineal. J Clin Endocrinol Metab 1964;24:299–301.
26. , , , . Excretion of 6-hydroxymelatonin sulfate (6-OHMS) in siblings during childhood and adolescence. Neuroendocrinology 2003;78:241–3.
27. , , , et al. Qualitative and quantitative changes of melatonin levels in physiological and pathological aging and in centenarians. J Pineal Res 2004;36:256–61.
28. . Melatonin as a hypnotic: pro. Sleep Med Rev 2005;9:51–65.
29. , , , et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ 2006;332:385–93.
30. , , , et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 2005;9:41–50.
31. , . Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med 2004;5:523–32.
32. , , , . Circadian uses of melatonin in humans. Chronobiol Int 2006;23:403–12.
33. , , , et al. Melatonin in circadian rhythm sleep disorders. In , , eds. Neuroendocrine Correlates of Sleep/Wakefulness. New York: Springer; 2006: pp. 269–94.
34. , , , . Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet 1995;346:541–4.
35. , , , . Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res 2007;16:372–80.
36. , , , et al. Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes. Current Med Res Opin 2007; 23:2597–605.
37. , , , et al. Melatonin in mood disorders. World J Biol Psychiatry 2006;7:138–51.
38. , , . Melatonin for the treatment of sleep disturbances in major depressive disorder. Am J Psychiatry 1998;155:1119–21.
39. , , , , . Drug insight: the use of melatonergic agonists for the treatment of insomnia – focus on ramelteon. Nat Clin Pract Neurol 2007;3:221–8.
40. , , , . Could agomelatine be the ideal antidepressant?Expert Rev Neurother 2006;6:1595–608.
41. . Agomelatine targets a range of major depressive disorder symptoms. Curr Opin Investig Drugs 2006;7:670–80.
42. , , , et al. Gender, cognitive decline, and risk of AD in older persons. Neurology 2003;60:1777–81.
43. , . The cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 2003;306:821–7.
44. , , , et al. The oxidation products of melatonin derivatives exhibit acetylcholinesterase and butyrylcholinesterase inhibitory activity. J Pineal Res 2008;45:40–9.
45. , , , et al. Daily variation in the concentration of melatonin and 5-methoxytryptophol in the human pineal gland: effect of age and Alzheimer’s disease. Brain Res 1990;528:170–4.
46. , , , . Daily rhythm of serum melatonin in patients with dementia of the degenerate type. Brain Res 1996;717:154–9.
47. , , , , . Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer’s disease, and apolipoprotein E-epsilon4/4 genotype. J Clin Endocrinol Metab 1999;84:323–7.
48. , , , et al. Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer’s type with disturbed sleep-waking. Biol Psychiatry 1999;45:417–21.
49. , , , et al. Daily rhythm of serum melatonin levels and effect of light exposure in patients with dementia of the Alzheimer’s type. Biol Psychiatry 1999;45:1646–52.
50. , , , et al. Pineal and pituitary-adrenocortical function in physiological aging and in senile dementia. Exp Gerontol 2000;35:1239–50.
51. , . The human pineal gland and melatonin in aging and Alzheimer’s disease. J Pineal Res 2005;38:145–52.
52. , . Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol Aging 1995;16:271–8.
53. , . Evolution of neuronal changes in the course of Alzheimer’s disease. J Neural Transm 1998;53(Suppl.):127–40.
54. , , , et al. Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. J Clin Endocrinol Metab 2003;88:5898–906.
55. , , , , . Early neuropathological Alzheimer’s changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res 2003;35:125–30.
56. , , , . Effects of melatonin in elderly patients with sleep disturbance. A pilot study. Curr Ther Res 1997;58:990–1000.
57. , , . Melatonin effects on sleep, mood, and cognition in elderly with mild cognitive impairment. J Pineal Res 1998;25:177–83.
58. , , , . Supplementary administration of artificial bright light and melatonin as potent treatment for disorganized circadian rest-activity and dysfunctional autonomic and neuroendocrine systems in institutionalized demented elderly persons. Chronobiol Int 2000;17:419–32.
59. , , . Melatonin for treatment of sundowning in elderly persons with dementia: a preliminary study. Arch Gerontol Geriatr 2000;31:65–76.
60. , , , , . Melatonin treatment of day-night rhythm disturbances and sundowning in Alzheimer disease: an open-label pilot study using actigraphy. J Clin Psychopharmacol 2004;24:456–9.
61. , , . Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer’s disease. Neuroendocrinol Lett 1998;19:111–5.
62. , , , . The use of melatonin in Alzheimer’s disease. Neuroendocrinol Lett 2002;23(Suppl. 1):20–3.
63. , , , et al. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J Nippon Med Sch 2003;70:334–41.
64. , , , et al. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer’s disease. Sleep 2003;26:893–901.
65. , , , et al. An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer’s disease. J Neural Transm 2000;107:203–31.
66. , , , et al. Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer’s disease. J Am Geriatr Soc 2008;56:239–46.
67. , . Amnestic MCI or prodromal Alzheimer’s disease?Lancet Neurol 2004;3:246–8.
68. , , . Possible therapeutic value of melatonin in mild cognitive impairment: a retrospective study. J Pineal Res 2007;43:404–9.
69. , , , et al. The neuroprotective activities of melatonin against the Alzheimer beta-protein are not mediated by melatonin membrane receptors. J Pineal Res 2002;32:135–42.
70. , , , , . Melatonin: a potent endogenous hydroxyl radical scavenger. Endocr J 1993;1:57–60.
71. , , , et al. The potential of melatonin in reducing morbidity-mortality after craniocerebral trauma. J Pineal Res 2007;42:1–11.
72. , , . AFMK, a melatonin metabolite, attenuates X-ray-induced oxidative damage to DNA, proteins and lipids in mice. J Pineal Res 2007;42:386–93.
73. , , , et al. The amyloid beta protein induces oxidative damage of mitochondrial DNA. J Neuropathol Exp Neurol 1997;56:1356–62.
74. , , , , . Melatonin in Alzheimer’s disease and other neurodegenerative disorders. Behav Brain Funct 2006;2:15.
75. , . Role of melatonin in Alzheimer-like neurodegeneration. Acta Pharmacol Sin 2006;27:41–9.
76. , , , . Beneficial effects of melatonin in experimental models of Alzheimer disease. Acta Pharmacol Sin 2006;27:129–39.